Novo Holdings A S acquired a new stake in shares of Flexion Therapeutics Inc (NASDAQ:FLXN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 207,454 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,552,000. Flexion Therapeutics comprises 0.4% of Novo Holdings A S’s portfolio, making the stock its 27th biggest holding.

A number of other institutional investors and hedge funds also recently modified their holdings of FLXN. BNP Paribas Arbitrage SA increased its position in Flexion Therapeutics by 53,692.3% in the first quarter. BNP Paribas Arbitrage SA now owns 6,993 shares of the specialty pharmaceutical company’s stock worth $87,000 after buying an additional 6,980 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Flexion Therapeutics in the first quarter worth about $338,000. Raymond James Financial Services Advisors Inc. increased its position in Flexion Therapeutics by 46.2% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 106,164 shares of the specialty pharmaceutical company’s stock worth $1,325,000 after buying an additional 33,569 shares in the last quarter. Spark Investment Management LLC purchased a new stake in Flexion Therapeutics in the first quarter worth about $1,457,000. Finally, Wasatch Advisors Inc. increased its position in Flexion Therapeutics by 7.8% in the first quarter. Wasatch Advisors Inc. now owns 1,016,137 shares of the specialty pharmaceutical company’s stock worth $12,681,000 after buying an additional 73,751 shares in the last quarter. Institutional investors and hedge funds own 84.84% of the company’s stock.

In other Flexion Therapeutics news, insider Michael D. Clayman acquired 2,317 shares of the company’s stock in a transaction dated Thursday, August 8th. The stock was purchased at an average price of $10.85 per share, with a total value of $25,139.45. Following the completion of the purchase, the insider now directly owns 72,249 shares in the company, valued at approximately $783,901.65. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 16.01% of the company’s stock.

FLXN has been the subject of a number of analyst reports. BidaskClub upgraded Flexion Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 4th. Zacks Investment Research upgraded Flexion Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Saturday, August 10th. Northland Securities set a $20.00 price target on Flexion Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, September 10th. Finally, ValuEngine upgraded Flexion Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Ten research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of $23.57.

Shares of NASDAQ FLXN traded up $0.14 during mid-day trading on Wednesday, reaching $14.63. The company’s stock had a trading volume of 36,441 shares, compared to its average volume of 529,254. The firm has a market capitalization of $563.65 million, a PE ratio of -3.26 and a beta of 1.22. The company has a debt-to-equity ratio of 3.95, a current ratio of 7.80 and a quick ratio of 7.33. The stock has a fifty day moving average of $11.72 and a two-hundred day moving average of $11.69. Flexion Therapeutics Inc has a 52 week low of $8.76 and a 52 week high of $20.04.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings data on Tuesday, August 6th. The specialty pharmaceutical company reported ($0.96) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.10. The firm had revenue of $16.95 million during the quarter, compared to analyst estimates of $14.03 million. Flexion Therapeutics had a negative return on equity of 175.29% and a negative net margin of 368.31%. Analysts anticipate that Flexion Therapeutics Inc will post -4.02 EPS for the current fiscal year.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States.

See Also: Moving Average – How it Helps Investors in Stock Selection

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.